highperformr logo

Aligos Therapeutics's Overview

Total employees82
HeadquartersSouth San Francisco
Founded2018

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to pioneering and developing novel therapeutic agents to address significant unmet medical needs in viral diseases and liver diseases. The company's primary focus is on creating targeted therapies for chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), and coronaviruses. Aligos leverages its expertise in virology, liver disease, and drug discovery to advance a portfolio of differentiated drug candidates designed to improve patient outcomes.

Where is Aligos Therapeutics's Headquarters?

HQ Function

The headquarters serves as the central hub for Aligos' research and development, clinical operations, corporate strategy, and administrative functions. It's where key decisions are made, and scientific innovation is driven.

Notable Features:

Located in a modern biotech park, the facility likely features state-of-the-art laboratory spaces and collaborative work environments conducive to scientific research. Specific architectural details are not publicly highlighted.

Work Culture:

As a clinical-stage biopharmaceutical company, the work culture at Aligos HQ is likely dynamic, science-driven, and collaborative, with a strong emphasis on innovation, results, and addressing unmet medical needs. Employees are often highly skilled and passionate about drug development.

HQ Significance:

The South San Francisco location provides Aligos with access to a rich ecosystem of talent, research institutions, potential partners, and venture capital, crucial for a biopharmaceutical company's growth and success.

Values Reflected in HQ: The headquarters' focus on R&D and its strategic location likely reflect Aligos' commitment to scientific excellence, innovation, and collaboration in tackling challenging diseases.

Location:

While headquartered in South San Francisco, USA, Aligos Therapeutics maintains a global outlook in its operations, particularly in clinical development. The company supports its research and clinical trials internationally, with a notable presence in Shanghai, China, to facilitate clinical development and operations in the Asia-Pacific region. This global approach allows Aligos to access diverse patient populations and collaborate with international research institutions and experts to advance its therapeutic pipeline for viral and liver diseases.

Street Address:

1 Corporate Drive, 2nd Floor

City:

South San Francisco

State/Province:

CA

Country:

USA

Aligos Therapeutics's Global Presence

Shanghai, China

Address: [Specific address not publicly available]

Facilitates engagement with regional clinical trial sites, investigators, and regulatory authorities, and supports the global development strategy by tapping into local expertise and patient populations.

Buying Intent Signals for Aligos Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Aligos Therapeutics

As of April 2025, Aligos Therapeutics' leadership includes:

Lawrence M. Blatt, Ph.D., MBA - Chairman and Chief Executive Officer
Lesley Ann Calhoun, J.D., Ph.D. - Chief Financial Officer and General Counsel
Lucinda Y. Quan, M.D., Ph.D. - Chief Medical Officer and Head of Drug Development
James Scopa, M.D., MBA - Chief Business Officer

Investors of Aligos Therapeutics

Aligos Therapeutics has been backed by several prominent investors over the years, including:

Versant Venture Capital
Wellington Management
BlackRock
The Vanguard Group
Roche Finance LTD
Pivotal bioVenture Partners
Perceptive Advisors LLC
Matrix Capital Management

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits1

In the past year, Aligos Therapeutics has seen key changes in its executive team, including the appointment of a new Chief Business Officer and the departure of its Chief Scientific Officer. These changes reflect the company's evolving strategic priorities as it advances its clinical programs.

Departures

Matthew W. McClure, M.D., Matthew W. McClure departed from his role as Chief Scientific Officer.

New Appointments:

James Scopa, M.D., MBA, James Scopa appointed as Chief Business Officer.

Technology (Tech Stack) used by Aligos Therapeutics

Discover the tools Aligos Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Aligos Therapeutics Email Formats and Examples

Aligos Therapeutics primarily utilizes the email format combining the first initial of an employee's first name with their full last name, followed by '@aligos.com'. This is a common convention in many corporations, facilitating straightforward communication.

firstinitial + last@aligos.com

Format

lblatt@aligos.com

Example

85%

Success rate

News and media

Aligos Therapeutics / GlobeNewswireMay 9, 2024

Aligos Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Aligos Therapeutics announced its financial results for Q1 2024, highlighting progress in its CHB and MASH clinical programs, including ongoing Phase 1 studies for ALG-000184 and initiation of dosing for ALG-055009. The company also outlined its strategic priorities and upcoming milestones....more

Aligos Therapeutics / GlobeNewswireApril 2, 2024

Aligos Therapeutics Doses First Subject in Phase 1 Study of MASH Candidate ALG-055009

Aligos announced the dosing of the first subject in its Phase 1 first-in-human clinical trial for ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH)....more

Aligos Therapeutics / GlobeNewswireMarch 21, 2024

Aligos Therapeutics Announces Departure of Chief Scientific Officer

Aligos Therapeutics announced that Matthew W. McClure, M.D., Chief Scientific Officer, will be departing the company effective March 25, 2024. Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO, will assume Dr. McClure’s responsibilities on an interim basis....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Aligos Therapeutics, are just a search away.